Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge M W Verberk

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|November 19, 2019
CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controlsLinda P Oosterveld, Inge M W Verberk, Nour K Majbour, et al.
Alzheimer'S Research & Therapy|February 14, 2024
The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's diseaseShreyasee Das, Marie-Paule E van Engelen, Julie Goossens, et al.
Annals of Neurology|September 10, 2018
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological ChangesInge M W Verberk, Rosalinde E Slot, Sander C J Verfaillie, et al.
The Lancet. Healthy Longevity|September 13, 2022
Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort studyInge M W Verberk, Malika B Laarhuis, Karlijn A van den Bosch, et al.
Annals of Neurology|June 14, 2019
Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathyFloor C Loonstra, Inge M W Verberk, Martijn T Wijburg, et al.
Frontiers in Neurology|July 25, 2025
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathologyDavid Wilson, Meenakshi Khare, Gallen Triana-Baltzer, et al.
Neurobiology of Aging|October 3, 2021
BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe projectKarlijn A van den Bosch, Inge M W Verberk, Jarith L Ebenau, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 23, 2022
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementiaElisabeth H Thijssen, Inge M W Verberk, Jana Kindermans, et al.
JAMA Neurology|September 20, 2021
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer DiseaseShorena Janelidze, Charlotte E Teunissen, Henrik Zetterberg, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 25, 2024
Performance of plasma p-tau217 and NfL in an unselected memory clinic settingRebecca Z Rousset, Thomas Claessen, Argonde C van Harten, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Movement Disorders : Official Journal of the Movement Disorder Society|November 19, 2019
CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controlsLinda P Oosterveld, Inge M W Verberk, Nour K Majbour, et al.
Alzheimer'S Research & Therapy|February 14, 2024
The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's diseaseShreyasee Das, Marie-Paule E van Engelen, Julie Goossens, et al.
Annals of Neurology|September 10, 2018
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological ChangesInge M W Verberk, Rosalinde E Slot, Sander C J Verfaillie, et al.
The Lancet. Healthy Longevity|September 13, 2022
Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort studyInge M W Verberk, Malika B Laarhuis, Karlijn A van den Bosch, et al.
Annals of Neurology|June 14, 2019
Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathyFloor C Loonstra, Inge M W Verberk, Martijn T Wijburg, et al.
Frontiers in Neurology|July 25, 2025
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathologyDavid Wilson, Meenakshi Khare, Gallen Triana-Baltzer, et al.
Neurobiology of Aging|October 3, 2021
BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe projectKarlijn A van den Bosch, Inge M W Verberk, Jarith L Ebenau, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 23, 2022
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementiaElisabeth H Thijssen, Inge M W Verberk, Jana Kindermans, et al.
JAMA Neurology|September 20, 2021
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer DiseaseShorena Janelidze, Charlotte E Teunissen, Henrik Zetterberg, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 25, 2024
Performance of plasma p-tau217 and NfL in an unselected memory clinic settingRebecca Z Rousset, Thomas Claessen, Argonde C van Harten, et al.
Pageof 8